SCHEMBL6038656

SCHEMBL6038656

Cc1ccc(S(=O)(=O)Nc2nccnc2OCCCOCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.51
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP19A1 P11511 1/20 0.44
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CCR2 P41597 1/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
EDNRA P25101 3/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039144 0.89 AR (0.60) ARMEN1KMT2ACYP19A1ALDH1A1
SCHEMBL6039097 0.88 MEN1 (0.48) ARMEN1KMT2AKDM4EPOLB
SCHEMBL6038757 0.87 AR (0.47) ARMEN1KMT2AKDM4EPOLB
SCHEMBL6038918 0.86 AR (0.49) ARMEN1KMT2AKDM4EPOLB
SCHEMBL6038624 0.85 KMT2A (0.60) ARMEN1KMT2AKDM4EPOLB
SCHEMBL6038954 0.83 KMT2A (0.50) ARMEN1KMT2AKDM4EPOLB
SCHEMBL6038605 0.82 KMT2A (0.54) ARMEN1KMT2ACYP19A1POLB
SCHEMBL6038710 0.82 AR (0.53) ARMEN1KMT2ACYP19A1KDM4E
SCHEMBL6038784 0.81 LIMK2 (0.45) ARMEN1KMT2AALDH1A1CCR2
SCHEMBL6038663 0.80 LMNA (0.53) ARMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 AR 422/4885MEN1 2431/4885KMT2A 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.